Next-Generation ON-Bipolar-Targeted Optogenetic Therapy Using Enhanced Photosensitive Protein and Promoter Achieves Durable Vision Restoration in Retinal Degeneration (ARVO 2026) - May 8, 2026 - Abstract #2547; Pres time: May 5, 2026; 09:15 AM - 09:30 AM; Location: Mile High 4A; P1 | "This next-generation optogenetic therapy delivers durable, cortex-level vision restoration via a clinically practical intravitreal route. Supported by previous IIT and IND clearances for ZM-02, these data establish a powerful foundation for human translation and global clinical expansion of safe, effective gene therapies for end-stage retinal degeneration."
First-in-human • Ophthalmology • Retinal Disorders
|
|
Yin Shen1; Lingbo Zhou1; Yu Li1; Sanwei Jiang1; Qiulin Song1; Shiqiang Gao3; Yang Wu2; Sen Jin4; Jingjing Cao4
|